Sources

10 Total Sources

The Lancet Publishes Deramiocel Phase 3 Data Showing 54% Slower DMD Decline

Center100%

Yahoo Finance7d ago

The Lancet Publishes Capricor's Deramiocel HOPE-3 Data for Duchenne Muscular Dystrophy

Cedars-Sinai7d ago

DMD Potential Therapy Preserves Heart, Arm Function

StockTitan7d ago

Capricor: Lancet Publishes HOPE-3 54% Slower Decline | CAPR Stock News

Medpage Today7d ago

FDA Committee Votes Down Duchenne Drug | MedPage Today

PRISM MarketView on X: "🚨 The Lancet has published Capricor's $CAPR Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy. Key result: 54% slower upper-limb decline vs. placebo (p=0.03), plus cardiac

Neurology Live7d ago

FDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA reviewers vote against approval of Capricor's DMD therapy in chaotic adcomm meeting - BioSpace

Stocktwits6d ago

Capricor's DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown – CEO Says Publication 'Reinforce Our Confidence' For Approval

Marketscreener.com7d ago

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy | MarketScreener

vantafin.com7d ago

Capricor's Deramiocel Faces FDA Advisory Committee Today: What Investors Need to Know | Vantafin